Image – Interventional flashlight

DOI: 10.4244/EIJ-D-20-00244

Transcatheter treatment of multivalvular heart disease

Mirjam Gauri Winkel1, MD; Nicolas Brugger1, MD; Lukas Hunziker1, MD; Stephan Windecker1, MD; Fabien Praz1, MD

Figure 1. Transcatheter treatment of multivalvular disease. A) Baseline severe MR, transthoracic echocardiography. B) Result after implantation of one PASCAL device (asterisk) with mild residual MR. C) Transcatheter tricuspid direct annuloplasty with a Cardioband after placement of 17 screws before (2D diameter 4.1 cm) and (D) after (2D diameter 3.2 cm) cinching of the annulus (arrow: approximate annular diameter). E) Baseline TR, transthoracic echocardiography. F) Result after annuloplasty with residual TR grade 1+. G) Evolution of NT-proBNP (pg/ml) and eGFR (ml/min) at the time of transcatheter mitral valve repair (TMVR), follow-up, transcatheter tricuspid valve repair (TTVR) and 30 days after both procedures.

A 78-year-old female patient with multivalvular heart disease and previous biventricular cardiac decompensation was referred for treatment. Echocardiography revealed moderate-to-severe primary mitral regurgitation (MR) (vena contracta [VC] 7.5 mm) (Figure 1A), as well as secondary severe tricuspid regurgitation (TR) (VC 7.2 mm, hepatic systolic backflow) (Figure 1E). Left ventricular function was moderately impaired (left ventricular ejection fraction [LVEF] 35%) with normal dimensions and no coronary artery disease. The right ventricle showed mild dilation and dysfunction. The EuroSCORE II of 4.3% was indicative of increased surgical risk, so that, respecting the patient’s preference, a percutaneous approach was selected by the Heart Team.

A two-step approach with treatment of the mitral valve first was chosen to address the recent left heart decompensation and account for possible improvement of TR after correction of MR. The patient underwent transcatheter mitral valve repair with one PASCAL implant (Edwards Lifesciences, Irvine, CA, USA) (Figure 1B), reducing MR severity to mild without stenosis (mean gradient [mGd] 3 mmHg). Despite a sustained good result on the mitral side, the patient reported persistent dyspnoea at three months, presumably due to persistent severe TR. In the presence of predominant annular dilation leading to a centrally located TR jet, transcatheter tricuspid annuloplasty using the Cardioband system (Edwards Lifesciences) was performed (Figure 1C, Figure 1D), reducing TR severity to grade 1+ (mGd 2 mmHg) (Figure 1F). At 30 days, the patient was free of symptoms and laboratory examination revealed a significant decrease of NT-proBNP, as well as improvement of kidney function, that were not present after isolated treatment of the mitral valve (Figure 1G).

This case illustrates the combination of different transcatheter techniques to address concomitant disease of the atrioventricular valves. Although economic aspects have to be considered and futility avoided, this case also emphasises the incremental clinical impact of the treatment of concomitant severe TR.

Conflict of interest statement

S. Windecker reports having received research grants to the institution from Abbott, Amgen, Bayer, BMS, Biotronik, Boston Scientific, CSL Behring, Edwards Lifesciences, Medtronic, Polares and Sinomed. The other authors have no conflicts of interest to declare.

Supplementary data

To read the full content of this article, please download the PDF.

Volume 16 Number 10
Nov 20, 2020
Volume 16 Number 10
View full issue


Key metrics

Suggested by Cory

Image – Interventional flashlight

10.4244/EIJ-D-21-00243 Dec 3, 2021
Iatrogenic interatrial shunt reversal with transcatheter tricuspid valve repair
Tavlaki E et al
free

10.4244/EIJV11SWA37 Sep 17, 2015
Tricuspid valve interventions in 2015
Lauten A and Figulla HR
free

10.4244/EIJV12SYA28 Sep 18, 2016
Percutaneous interventional options for the treatment of tricuspid regurgitation
Haude M and Prendergast B
free

10.4244/EIJV15I10A159 Nov 15, 2019
The five Ws of transcatheter tricuspid valve repair: Who, What, When, Where, and Why
Williams A et al
free

EXPERT REVIEW

10.4244/EIJ-D-17-00571 Sep 24, 2017
The big parade: emerging percutaneous mitral and tricuspid valve devices
Natarajan D et al
free

Image – Interventional flashlight

10.4244/EIJ-D-21-00614 Dec 17, 2021
Transfemoral transcatheter tricuspid valve replacement after failed leaflet repair
Wild M et al
free

TRICUSPID VALVE INTERVENTIONS

10.4244/EIJV12SYA29 Sep 18, 2016
Transcatheter interventions for tricuspid regurgitation: MitraClip
Schueler R et al
free
Trending articles
151.43

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
55.9

Clinical research

10.4244/EIJ-D-22-00621 Feb 20, 2023
Long-term changes in coronary physiology after aortic valve replacement
Sabbah M et al
free
54.9

Expert review

10.4244/EIJ-D-21-01010 Jun 24, 2022
Device-related thrombus following left atrial appendage occlusion
Simard T et al
free
43.75

Clinical Research

10.4244/EIJ-D-21-01091 Aug 5, 2022
Lifetime management of patients with symptomatic severe aortic stenosis: a computed tomography simulation study
Medranda G et al
free
39.95

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved